8/31/2026 – Genetic Counseling for Families Touched by an Inherited/Germline Mutation Webinar
8/31/2026 – Genetic Counseling for Families Touched by an Inherited/Germline Mutation Webinar
Click here for the presentation slides.
Predicting Radiation Side Effects – PROSTOX Webinar with interesting updates!
Predicting Radiation Side Effects – PROSTOX Webinar with interesting updates!
Last year, we presented a webinar on predicting Prostate Cancer Radiation Treatment side effects with PROSTOX before treatment begins. By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.
PROSTOX Standard (previously PROSTOX CFRT+) predicts late grade ≥2 toxicity from conventionally fractionated (CFRT) or moderately hypofractionated (MHFRT) radiation therapy for patients with localized prostate cancer. Together with PROSTOX Ultra, which is already available for patients considering stereotactic body radiation therapy (SBRT), the PROSTOX portfolio now provides risk assessment across a broader range of external beam radiation therapy (EBRT) types. We’ll discuss the updates and other patient concerns, such as insurance coverage and questions to bring to your doctors.
To find a copy of the slides, click here.
AnCan Keynote at Houston Methodist, Aug 2024 – Can you hear us? Amplifying the patient voice.
AnCan Keynote at Houston Methodist, Aug 2024 – Can you hear us? Amplifying the patient voice.
“Playing the Long Game” – Does your Recurrent/Advanced Prostate Cancer Need Treating? NCI Seminar
“Playing the Long Game” – Does your Recurrent/Advanced Prostate Cancer Need Treating?
National Cancer Institute Seminar with Dr. Ravi Madan and Dr. Melissa Abel, Jan 30, 2026
READ THROUGH – you won’t regret it!! (rd)
A recent article in the Journal of Clinical Oncology with a very dry title caught our eye – National Cancer Institute’s Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
AnCan has long been perplexed by the prostate cancer category “non-metastatic Castrate Resistant” or even “non-metastatic Hormone Sensitive”. If PSA is rising after primary treatment but prior to hormone treatment, something’s going on, however, ‘micro-metastatic’. It’s like being just a little bit pregnant!!
This paper considers a new category, PSMA Positive Biochemically Recurrent – PSMA+ BCR. We circulated the paper to our Brains Trust and reached out to Dr. Ravi Madan at the National Cancer Institute (NCI) with a couple of questions. Dr Madan offered to meet with us along with his colleague, Dr. Melissa Abel. What resulted was this REMARKABLE video that could present many of our recurrent and advanced AnCan (& non-AnCan) participants with one of the most mind-blowing videos many have seen in a long time,
DO YOU REALLY NEED TREATMENT??
As the venerable and highly respected Dr. Paul Schellhammer said in the meeting, “it’s like listening 15 years ago to the folks who began to promote active surveillance ( in first line treatment)” Dr. Madan and Dr. Abel have collected solid data from around 150 patients that suggests men with slow PSA doubling times can “play the long game” as Dr. Ravi calls it, and defer active treatment when their disease recurs.
PLEASE watch this astonishing presentation, listen to some excellent observations and questions, and consider how it relates to your own situation. And spread the word to others. Dr. Madan’s and Dr. Abel’s NCI clinical trial can be found at https://www.clinicaltrials.gov/study/NCT05588128. Don’t immediately assume you’re not eligible before speaking with them… but you’ll have to watch the video to get their contact information.
See this related report on a UCLA study reported in the JNCCN Feb 2025
Living with Visual Snow – a Therapist’s Perspective with Dr. Paula Hechinger – January 20th, 2025
Living with Visual Snow – a Therapist’s Perspective with Dr. Paula Hechinger
“My approach to Visual Snow Syndrome was born from my own journey from being a
depressed and isolated mother of two to becoming a resilient psychoanalyst. Today, I not
only help individuals navigate VSS but also support those facing a wide range of mental
health challenges, including depression, bipolar disorder, anxiety, borderline personality
disorder, trauma, and more. What once felt like a limitation became the foundation of my
purpose to guide others toward healing with empathy, depth, and lived understanding.” -Dr. Paula Hechinger
Join us for a special presentation with Dr. Paula Hechinger, a psychoanalyst who is living with Visual Snow Syndrome. She shares her personal journey, insights, and practical tips for managing VSS. Click Here to view her personal testimony and presentation.
For a list of resources on Visual Snow Syndrome (VSS), click here.
Special Presentation: What if You Could Predict the Risk of Radiation Effects – Prostox and Beyond
Special Presentation: What if You Could Predict the Risk of Radiation Effects – Prostox and Beyond
Featuring Dr. Joanne Weidhaas, developer of the Prostox test. Dr. Weidhaas is a radiation oncologist/ professor at UCLA. Co-discoverer of the biomarker KRAS-variant, she co-founded MiraDx, maker of Prostox, and MiraKind to empower individuals with meaningful health information. Dr. Weidhass’ professional and academic resume includes MSKCC, Yale and Stanford, largely in breast cancer. She also finds time to care for 3 kids and save dogs!
Learn more about Prostox here: https://miradx.com/prostox/